Neurostimulation Devices Market Analysis 2026

Competitive Landscape of the Neurostimulation Devices Market

The neurostimulation devices market is highly competitive, with key players focusing on technological innovations, strategic partnerships, and mergers to enhance their product portfolios. Major companies such as Medtronic, Boston Scientific, Abbott, and Nevro Corporation dominate the market. They offer a range of products, including deep brain stimulation (DBS) devices, spinal cord stimulators (SCS), and transcranial magnetic stimulation (TMS) systems. These firms are investing in R&D to develop more effective and patient-friendly devices, such as wireless and rechargeable models. The market is also witnessing increasing competition from new entrants and regional players focusing on emerging markets.

In June 2024, Nexalin Technology's second-generation 15 mA neurostimulation device was approved by ANVISA, Brazil. This was the device's third clearance, following China and Oman. https://www.stocktitan.net/news/NXL/nexalin-technology-ceo-provides-letter-to-7awc57cpkubf.html

In January 2024, Abbott's Liberta RC, a cutting-edge rechargeable deep brain stimulator (DBS) system designed to alleviate movement disorders, received FDA approval. This innovative technology offers a new ray of hope for individuals grappling with conditions like Parkinson's disease and essential tremor. The Liberta RC system stands out with its unique features, including the world's smallest rechargeable implantable pulse generator (IPG) and the longest-lasting battery charge among available DBS devices. https://www.abbott.com/corpnewsroom/products-and-innovation/liberta-rc-dbs-system-is-fda-approved-3-things-to-know.html

In November 2024, Nevro Corporation introduced the groundbreaking HFX iQ Spinal Cord Stimulation System, designed to tailor the treatment of chronic pain. This system is the first and only spinal cord stimulation (SCS) device that incorporates artificial intelligence (AI) technology, utilizing high-frequency (10 kHz) therapy based on significant clinical evidence. It leverages continuous cloud data insights to provide customized pain relief.
https://nevro.com/English/us/investors/investor-news/investor-news-details/2024/Nevros-HFX-iQ-Spinal-Cord-Stimulation-with-AI-Technology-Receives-CE-Mark-Certification-in-Europe-Increasing-Product-Expansion-Globally/default.aspx 
In April 2023, Synapse Biomedical Inc. obtained FDA premarket approval (PMA) for the NeuRx Diaphragm Pacing System (NeuRx DPS). This battery-operated device delivers electrical stimulation to the diaphragm through four percutaneous intramuscular electrodes, which are implanted using minimally invasive laparoscopy. It is intended to assist patients with spinal cord injuries who depend on mechanical ventilation.
https://www.synapsebiomedical.com/synapse-biomedical-wins-new-pma-approval/ 
In May 2023, Abbott received FDA approval for its spinal cord stimulation (SCS) systems aimed at treating chronic back pain in individuals who have not undergone or are not candidates for back surgery, referred to as non-surgical back pain. This new indication encompasses all of Abbott's SCS products available in the United States, including the Eterna SCS platform and the Proclaim SCS family.
https://abbott.mediaroom.com/2023-05-16-Abbott-Receives-FDA-Approval-for-Its-Spinal-Cord-Stimulation-Systems-to-Treat-Chronic-Back-Pain-in-People-Who-Have-Limited-Surgical-Options#:~:text=ABBOTT%20PARK%2C%20Ill.%2C%20May,surgery%2C%20known%20as%20non%2Dsurgical 
In January 2023, Axonics, Inc. announced that the U.S. FDA had approved the Axonics R20 neurostimulator, an enhanced version of the Axonics R15, intended for the treatment of chronic conditions such as overactive bladder, with a lifespan of at least 20 years.
https://ir.axonics.com/news-releases/news-release-details/axonics-receives-fda-approval-fourth-generation-rechargeable#:~:text=The%20newly%20approved%20Axonics%20R20,months%20for%20only%20one%20hour
In September 2022, Neuronetics Inc. unveiled enhancements to the NeuroStar Advanced Therapy’s proprietary TrakStar Platform. The TrakStar upgrades feature a more user-friendly interface that facilitates the quick sorting and prioritization of potential patients. Additionally, it streamlines the patient experience by integrating the proprietary PHQ-10 platform with the HIPAA-compliant TrakStar patient data management system, simplifying the identification of new patients and those requiring re-treatment.
https://ir.neuronetics.com/news-releases/news-release-details/neuronetics-launches-innovations-neurostarr-advanced-therapys/ 
 

SY

Supriya Yadav Verified Analyst

Research Analyst at Cognitive Market Research · Cognitive Market Research

Supriya is a Team Lead at Cognitive Market Research & Consulting, leading research initiatives and strategic intelligence projects across the Healthcare, Pharmaceuticals, and Medical Devices & Consumables sectors. With more than two years of experience in market research and data analysis, she plays a key role in helping organizations navigate complex healthcare ecosystems, identify emerging opportunities, and make informed business decisions through data-driven insights and market intelligence.

Combining expertise in both primary and secondary research methodologies with a strong academic foundation in Marketing and Finance, Supriya oversees the execution of market assessments, competitive intelligence studies, forecasting models, stakeholder interviews, trend analysis, and custom consulting engagements. She collaborates with healthcare providers, pharmaceutical manufacturers, medical device companies, industry experts, and other key stakeholders to gather firsthand market perspectives while validating findings through extensive  research. Her ability to interpret clinical, commercial, and market data enables clients to better understand industry developments, regulatory influences, innovation trends, and competitive dynamics.

In her leadership role, she manages end-to-end research projects and guides cross-functional teams in delivering high-quality market reports, consulting solutions, and strategic studies. Her expertise in market estimation, forecasting, and analytical modeling helps organizations evaluate market potential, assess growth opportunities, strengthen competitive positioning, and support strategic planning initiatives. By transforming complex healthcare and life sciences data into actionable business intelligence, she enables clients to make confident decisions in rapidly evolving market environments.

Driven by a passion for healthcare innovation and continuous professional development, Supriya remains committed to staying ahead of industry trends, technological advancements, and changing market conditions. Her leadership, analytical mindset, and dedication to research excellence help organizations mitigate risks, capitalize on emerging opportunities, and achieve sustainable growth across the global healthcare and life sciences landscape.

Read more

LinkedIn Profile Book Appointment